SEC Form 3 
FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0104	
Estimated average burden	
hours per response:	0.5	

	
1. Name and Address of Reporting Person*
CHEN JIN-LONG	

(Last)	(First)	(Middle)	
333 OYSTER POINT BOULEVARD	

(Street) 
SOUTH SAN FRANCISCO	CA	94080	

(City)	(State)	(Zip)	
	2. Date of Event Requiring Statement (Month/Day/Year)
04/03/2019 	3. Issuer Name and Ticker or Trading Symbol 
NGM BIOPHARMACEUTICALS INC [ NGM ] 		
		4. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
X	Director		10% Owner	
X	Officer (give title below)		Other (specify below)	
Chief Scientific Officer	
	5. If Amendment, Date of Original Filed (Month/Day/Year)				
			6. Individual or Joint/Group Filing (Check Applicable Line) 
X	Form filed by One Reporting Person	
	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Beneficially Owned	
1. Title of Security (Instr. 4) 	2. Amount of Securities Beneficially Owned (Instr. 4) 	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	4. Nature of Indirect Beneficial Ownership (Instr. 5) 	
Common Stock	924,943(1) 	D		
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 4) 	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 	4. Conversion or Exercise Price of Derivative Security 	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	6. Nature of Indirect Beneficial Ownership (Instr. 5) 	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	(2) 	02/24/2020	Common Stock	143,500(1) 	0.52(1) 	D		
Stock Option (Right to Buy)	(2) 	02/10/2021	Common Stock	150,000(1) 	0.6(1) 	D		
Stock Option (Right to Buy)	(2) 	03/01/2022	Common Stock	150,500(1) 	1.44(1) 	D		
Stock Option (Right to Buy)	(2) 	01/23/2023	Common Stock	175,000(1) 	1.44(1) 	D		
Stock Option (Right to Buy)	(2) 	01/23/2024	Common Stock	175,000(1) 	2.16(1) 	D		
Stock Option (Right to Buy)	(2) 	01/30/2025	Common Stock	200,000(1) 	4(1) 	D		
Stock Option (Right to Buy)	(3) 	01/26/2026	Common Stock	225,000(1) 	7.64(1) 	D		
Stock Option (Right to Buy)	(4) 	01/19/2027	Common Stock	225,000(1) 	7.7(1) 	D		
Stock Option (Right to Buy)	(5) 	01/30/2028	Common Stock	200,000(1) 	8.14(1) 	D		
Stock Option (Right to Buy)	(6) 	02/06/2029	Common Stock	175,000(1) 	12.06(1) 	D		
Explanation of Responses:	
1. Reflects a 1-for-2 reverse stock split of the Company's issued and outstanding securities effective March 22, 2019.	
2. The shares subject to the stock option are fully vested.	
3. The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2016, with 1/48th of the shares vesting on a monthly basis.	
4. The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2017, with 1/48th of the shares vesting on a monthly basis.	
5. The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2018, with 1/48th of the shares vesting on a monthly basis.	
6. The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2019, with 1/48th of the shares vesting on a monthly basis.	
Remarks:	
	
	/s/ Jin-Long Chen	04/03/2019	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
POWER OF ATTORNEY
        Know all by these presents, that the undersigned hereby constitutes and
appoints each of William J. Rieflin, David Woodhouse, or Aetna Wun Trombley, or
any of them signing singly, and with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:
(1)     execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or more than 10% stockholder of NGM
Biopharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2)             do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the SEC and any stock exchange or similar authority; and
(3)     take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of August 28, 2018.

/s/ Jin-Long Chen
Jin-Long Chen, Ph.D.